Studies people living with HIV and their samples over time
Collects samples and health data from adults with HIV-1 to study the virus.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
- Status
- Recruiting
- People taking part
- 2,500 people, planned
- Started
- Mar 2000
- Expected to end
- Dec 2033
- Type of study
- Observational
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults living with HIV-1 who fit one of four groups, such as people not on HIV medicine or people about to start it. It follows them over time and stores samples.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- HIV-1 infection. People can join with one of these: viral load under 2000 copies/ml without HIV medicine; undetectable viral load on stable medicine with CD4 T-cells consistently under 350 for the last 12 months; never treated and planning to start; or HIV-positive 10 years or more without treatment and CD4 always above 500.
- Earlier treatment
- Some groups must be on a stable HIV medicine regimen. Some must have had no HIV medicine, or none for 10 years or more. One group has never taken HIV medicine and plans to start.
- Biomarker or test result
- HIV viral load and CD4 T-cell counts, as listed in each group.
Main reasons for not taking part
- Active opportunistic infection, or treatment for one in the last 4 months (oral candidiasis is acceptable)
- Active treatment for cancer
- Active treatment for hepatitis C that needs interferon-based therapy
- Immunosuppressive therapy in the last 4 months
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- SCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria:
- Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy
- Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen
- Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable
- Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500
Who cannot take part
- Immunosuppressive therapy taken within the last 4 months
- Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)
- Active treatment for cancer
- Active treatment for hepatitis C requiring interferon based therapy
Where in United States
- San Francisco General HospitalSan Francisco, United StatesContact: Rebecca Hoh, M.S.Taking people
About the trial
What the trial wants to find out
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
- Plain-language title
- Studies people living with HIV and their samples over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 8 September 2026